Increased incidence of candidemia in critically ill patients during the Coronavirus Disease 2019 (COVID-19) pandemic
Main Author: | |
---|---|
Publication Date: | 2022 |
Other Authors: | , , , , , , , |
Format: | Article |
Language: | eng |
Source: | Brazilian Journal of Infectious Diseases |
Download full: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702022000200502 |
Summary: | Abstract Background Patients with severe Coronavirus Disease 2019 (COVID-19) are treated with corticosteroids. Aim We aimed to evaluate the role of corticosteroid treatment in candidemia development during the COVID-19 pandemic. Methods This retrospective study was conducted in a Greek ICU, from 2010 to August 2021, encompassing a pre-pandemic and a pandemic period (pandemic period: April 2020 to August 2021). All adult patients with candidemia were included. Results During the study period, 3,572 patients were admitted to the ICU, 339 patients during the pandemic period, of whom 196 were SARS-CoV-2-positive. In total, 281 candidemia episodes were observed in 239 patients, 114 in the pandemic period. The majority of candidemias in both periods were catheter-related (161; 50.4%). The incidence of candidemia in the pre-pandemic period was 5.2 episodes per 100 admissions, while in the pandemic period was 33.6 (p < 0.001). In the pandemic period, the incidence among COVID-19 patients was 38.8 episodes per 100 admissions, while in patients without COVID-19 incidence was 26.6 (p= 0.019). Corticosteroid administration in both periods was not associated with increased candidemia incidence. Conclusions A significant increase of candidemia incidence was observed during the pandemic period in patients with and without COVID-19. This increase cannot be solely attributed to immunosuppression (corticosteroids, tocilizumab) of severe COVID-19 patients, but also to increased workload of medical and nursing staff. |
id |
BSID-1_be2f3eb85646dc5994432c3011e70113 |
---|---|
oai_identifier_str |
oai:scielo:S1413-86702022000200502 |
network_acronym_str |
BSID-1 |
network_name_str |
Brazilian Journal of Infectious Diseases |
repository_id_str |
|
spelling |
Increased incidence of candidemia in critically ill patients during the Coronavirus Disease 2019 (COVID-19) pandemicCandidemiaCOVID-19SARS-CoV-2Critically-ill patientsICUCorticosteroidsAbstract Background Patients with severe Coronavirus Disease 2019 (COVID-19) are treated with corticosteroids. Aim We aimed to evaluate the role of corticosteroid treatment in candidemia development during the COVID-19 pandemic. Methods This retrospective study was conducted in a Greek ICU, from 2010 to August 2021, encompassing a pre-pandemic and a pandemic period (pandemic period: April 2020 to August 2021). All adult patients with candidemia were included. Results During the study period, 3,572 patients were admitted to the ICU, 339 patients during the pandemic period, of whom 196 were SARS-CoV-2-positive. In total, 281 candidemia episodes were observed in 239 patients, 114 in the pandemic period. The majority of candidemias in both periods were catheter-related (161; 50.4%). The incidence of candidemia in the pre-pandemic period was 5.2 episodes per 100 admissions, while in the pandemic period was 33.6 (p < 0.001). In the pandemic period, the incidence among COVID-19 patients was 38.8 episodes per 100 admissions, while in patients without COVID-19 incidence was 26.6 (p= 0.019). Corticosteroid administration in both periods was not associated with increased candidemia incidence. Conclusions A significant increase of candidemia incidence was observed during the pandemic period in patients with and without COVID-19. This increase cannot be solely attributed to immunosuppression (corticosteroids, tocilizumab) of severe COVID-19 patients, but also to increased workload of medical and nursing staff.Brazilian Society of Infectious Diseases2022-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702022000200502Brazilian Journal of Infectious Diseases v.26 n.2 2022reponame:Brazilian Journal of Infectious Diseasesinstname:Brazilian Society of Infectious Diseases (BSID)instacron:BSID10.1016/j.bjid.2022.102353info:eu-repo/semantics/openAccessPapadimitriou-Olivgeris,MatthaiosKolonitsiou,FevroniaKefala,SotiriaSpiliopoulou,AnastasiaAretha,DiamantoBartzavali,ChristinaSiapika,ArgyroMarangos,MarkosFligou,Fotinieng2022-06-07T00:00:00Zoai:scielo:S1413-86702022000200502Revistahttps://www.bjid.org.br/https://old.scielo.br/oai/scielo-oai.phpbjid@bjid.org.br||lgoldani@ufrgs.br1678-43911413-8670opendoar:2022-06-07T00:00Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID)false |
dc.title.none.fl_str_mv |
Increased incidence of candidemia in critically ill patients during the Coronavirus Disease 2019 (COVID-19) pandemic |
title |
Increased incidence of candidemia in critically ill patients during the Coronavirus Disease 2019 (COVID-19) pandemic |
spellingShingle |
Increased incidence of candidemia in critically ill patients during the Coronavirus Disease 2019 (COVID-19) pandemic Papadimitriou-Olivgeris,Matthaios Candidemia COVID-19 SARS-CoV-2 Critically-ill patients ICU Corticosteroids |
title_short |
Increased incidence of candidemia in critically ill patients during the Coronavirus Disease 2019 (COVID-19) pandemic |
title_full |
Increased incidence of candidemia in critically ill patients during the Coronavirus Disease 2019 (COVID-19) pandemic |
title_fullStr |
Increased incidence of candidemia in critically ill patients during the Coronavirus Disease 2019 (COVID-19) pandemic |
title_full_unstemmed |
Increased incidence of candidemia in critically ill patients during the Coronavirus Disease 2019 (COVID-19) pandemic |
title_sort |
Increased incidence of candidemia in critically ill patients during the Coronavirus Disease 2019 (COVID-19) pandemic |
author |
Papadimitriou-Olivgeris,Matthaios |
author_facet |
Papadimitriou-Olivgeris,Matthaios Kolonitsiou,Fevronia Kefala,Sotiria Spiliopoulou,Anastasia Aretha,Diamanto Bartzavali,Christina Siapika,Argyro Marangos,Markos Fligou,Fotini |
author_role |
author |
author2 |
Kolonitsiou,Fevronia Kefala,Sotiria Spiliopoulou,Anastasia Aretha,Diamanto Bartzavali,Christina Siapika,Argyro Marangos,Markos Fligou,Fotini |
author2_role |
author author author author author author author author |
dc.contributor.author.fl_str_mv |
Papadimitriou-Olivgeris,Matthaios Kolonitsiou,Fevronia Kefala,Sotiria Spiliopoulou,Anastasia Aretha,Diamanto Bartzavali,Christina Siapika,Argyro Marangos,Markos Fligou,Fotini |
dc.subject.por.fl_str_mv |
Candidemia COVID-19 SARS-CoV-2 Critically-ill patients ICU Corticosteroids |
topic |
Candidemia COVID-19 SARS-CoV-2 Critically-ill patients ICU Corticosteroids |
description |
Abstract Background Patients with severe Coronavirus Disease 2019 (COVID-19) are treated with corticosteroids. Aim We aimed to evaluate the role of corticosteroid treatment in candidemia development during the COVID-19 pandemic. Methods This retrospective study was conducted in a Greek ICU, from 2010 to August 2021, encompassing a pre-pandemic and a pandemic period (pandemic period: April 2020 to August 2021). All adult patients with candidemia were included. Results During the study period, 3,572 patients were admitted to the ICU, 339 patients during the pandemic period, of whom 196 were SARS-CoV-2-positive. In total, 281 candidemia episodes were observed in 239 patients, 114 in the pandemic period. The majority of candidemias in both periods were catheter-related (161; 50.4%). The incidence of candidemia in the pre-pandemic period was 5.2 episodes per 100 admissions, while in the pandemic period was 33.6 (p < 0.001). In the pandemic period, the incidence among COVID-19 patients was 38.8 episodes per 100 admissions, while in patients without COVID-19 incidence was 26.6 (p= 0.019). Corticosteroid administration in both periods was not associated with increased candidemia incidence. Conclusions A significant increase of candidemia incidence was observed during the pandemic period in patients with and without COVID-19. This increase cannot be solely attributed to immunosuppression (corticosteroids, tocilizumab) of severe COVID-19 patients, but also to increased workload of medical and nursing staff. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-01-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702022000200502 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702022000200502 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
10.1016/j.bjid.2022.102353 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
publisher.none.fl_str_mv |
Brazilian Society of Infectious Diseases |
dc.source.none.fl_str_mv |
Brazilian Journal of Infectious Diseases v.26 n.2 2022 reponame:Brazilian Journal of Infectious Diseases instname:Brazilian Society of Infectious Diseases (BSID) instacron:BSID |
instname_str |
Brazilian Society of Infectious Diseases (BSID) |
instacron_str |
BSID |
institution |
BSID |
reponame_str |
Brazilian Journal of Infectious Diseases |
collection |
Brazilian Journal of Infectious Diseases |
repository.name.fl_str_mv |
Brazilian Journal of Infectious Diseases - Brazilian Society of Infectious Diseases (BSID) |
repository.mail.fl_str_mv |
bjid@bjid.org.br||lgoldani@ufrgs.br |
_version_ |
1754209245431070720 |